London, UK – [Insert Date] – In a significant strategic pivot, British pharmaceutical giant GSK has announced the discontinuation of its late-stage development program for camlipixant, a P2X3 receptor antagonist, in the treatment of refractory chronic cough (RCC). This decision, which follows mixed results from pivotal Phase III trials, marks a substantial setback for the company’s ambitions in the RCC market and casts a shadow over the broader class of P2X3 receptor antagonists. While the program’s termination represents a lost opportunity estimated to be worth up to $1 billion, GSK is maintaining its commitment to camlipixant’s development in two forms of irritable bowel syndrome (IBS).
n
The move comes at a critical juncture for GSK, particularly in the wake of its substantial $2 billion bid for Bellus Health, a company whose lead asset, blaffen, is also a P2X3 receptor antagonist targeting chronic cough. The termination of the camlipixant RCC program effectively removes a potential competitor from the equation and may signal a re-evaluation of the P2X3 receptor antagonist landscape for cough indications.
n
The Disappointment of the CALM Trials: A Tale of Two Studies
n
The decision to halt camlipixant’s development for RCC is directly attributable to the disparate outcomes observed in the Phase III CALM-1 and CALM-2 studies. These trials were designed to rigorously assess the efficacy and safety of camlipixant in patients suffering from this debilitating and often intractable condition.
n
The CALM-1 study, conducted across 200 global locations, initially offered a glimmer of hope. A dosage of 50mg of camlipixant administered twice daily demonstrated statistically significant reductions in cough frequency over a 24-hour period when compared to a placebo, thereby meeting the trial’s primary endpoint at the 12-week mark. This result suggested that the P2X3 receptor antagonist mechanism held promise for alleviating the persistent cough experienced by patients with RCC.
n
However, this positive finding was not replicated in the CALM-2 study, which was conducted specifically in China. The drug failed to achieve statistical significance in reducing cough frequency in this geographically distinct patient population. This divergence in results immediately raised questions about the drug’s broad applicability and potential regional variations in its effectiveness, a crucial factor for a global pharmaceutical company like GSK.
n
Further compounding the challenges, a lower dosage of 25mg twice daily of camlipixant failed to demonstrate any significant impact on cough frequency or secondary endpoint measures in either the CALM-1 or CALM-2 studies. This lack of dose-response efficacy across both studies led GSK to conclude that the drug’s therapeutic benefit in RCC was, at best, "limited."
n
A Prudent, Yet Painful, Strategic Realignment
n
Despite the mixed efficacy signals, the safety and tolerability profile of camlipixant was deemed acceptable by GSK. The drug was found to be safe and well-tolerated by trial participants. However, the company has ultimately prioritized its strategic objectives and resource allocation, leading to the decision to discontinue the RCC program.
n
"While camlipixant has demonstrated a generally favorable safety and tolerability profile, the overall clinical data from the Phase III CALM studies indicate that the drug is unlikely to transform patient care in refractory chronic cough," a GSK spokesperson stated in a press release. "Therefore, we have made the difficult decision to discontinue the development of camlipixant for this indication."
n
This decision, while disappointing, is seen by analysts as a pragmatic move, especially considering GSK’s recent aggressive M&A strategy. Jefferies, a financial services firm, estimated that this move forecloses a "potential $1bn opportunity" in the RCC market for GSK. However, they also noted that the setback is "manageable" given the company’s recent focus on deals poised to bolster its revenue pipeline. The significant investment in Bellus Health, for instance, positions GSK to potentially benefit from a competing P2X3 receptor antagonist in the chronic cough space, albeit with the added complexity of integrating a newly acquired entity.
n
Shifting Gears: Camlipixant’s Promising Future in IBS
n
While the door has closed on camlipixant’s prospects in refractory chronic cough, GSK is not abandoning the drug entirely. The company remains committed to advancing camlipixant’s development in two distinct forms of irritable bowel syndrome (IBS). The ongoing Phase IIb BALANCE trial (NCT07519395) is actively investigating the drug’s efficacy and safety in this patient population. According to data from ClinicalTrials.gov, this trial is anticipated to conclude in March 2027.
n
The rationale behind this continued investment in IBS stems from the understanding that P2X3 receptors play a role in visceral hypersensitivity and pain signaling, which are key pathophysiological mechanisms in IBS. The potential for camlipixant to modulate these pathways offers a novel therapeutic approach for patients suffering from the often-debilitating symptoms of IBS, including abdominal pain, bloating, and altered bowel habits.
n
This strategic pivot underscores GSK’s broader commitment to its immunology and respiratory portfolios, while also exploring the broader therapeutic applications of its drug candidates. The successful development of camlipixant in IBS could represent a significant commercial opportunity, potentially offsetting the lost potential in the RCC market.
n
The Troubled Landscape of P2X3 Receptor Antagonists for Cough
n
The discontinuation of camlipixant from RCC development adds to a growing list of P2X3 receptor antagonists that have faced significant hurdles in this therapeutic area. The class of drugs, which targets the P2X3 receptor expressed on sensory neurons involved in cough reflex sensitization, has encountered a series of efficacy and safety challenges, leading to a challenging regulatory and development environment.
n
Prior to GSK’s decision, Bayer had already abandoned its P2X3 receptor antagonist, eliapixant, in 2022, citing concerns regarding the drug’s safety profile. This was not an isolated incident for Bayer; the German pharmaceutical giant had previously discontinued the development of filapixant, another P2X3 receptor antagonist, due to a higher incidence of taste disturbances associated with its use. These taste-related side effects, often referred to as dysgeusia, have been a recurring issue within the P2X3 antagonist class, impacting patient adherence and overall treatment experience.
n
Shionogi, a Japanese pharmaceutical company, also appears to have shelved its P2X3 receptor antagonist candidate, sivopixant. The drug is no longer listed in the company’s active pipeline. However, Shionogi is not entirely out of the P2X3 receptor antagonist space. Through a partnership with Apnimed, they are jointly developing SASS-01, a combination therapy comprising sivopixant and an undisclosed second compound, specifically for the treatment of sleep apnea. This indicates a potential shift in focus for the company within the broader therapeutic applications of P2X3 receptor antagonism.
n
A Market Seeking Solutions: The Unmet Need in RCC
n
The current therapeutic landscape for refractory chronic cough remains starkly underserved. There are currently no medications specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of RCC. Patients afflicted with this condition typically rely on off-label treatments, often involving neuromodulators such as gabapentin or tricyclic antidepressants. While these medications can offer some relief, they are not ideal solutions and often come with their own set of side effects and limited efficacy for many patients.
n
In contrast, MSD’s (Merck & Co.) P2X3-targeting therapy, Lyfnua (gefapixant), has secured regulatory approval in several key markets, including the UK, the European Union, Japan, and Switzerland. However, the FDA notably refused to grant approval for gefapixant in the United States, citing concerns about its perceived lack of efficacy in the intended patient population. This regulatory divergence highlights the complexities and stringent requirements for demonstrating robust clinical benefit in the treatment of RCC.
n
The discontinuation of camlipixant by GSK, coupled with the challenges faced by other P2X3 receptor antagonists, underscores the significant unmet medical need in refractory chronic cough. The development of truly effective and safe treatments for this condition remains a critical goal for pharmaceutical research and development. While the path forward for P2X3 receptor antagonists in cough may be fraught with challenges, the ongoing research and the potential for future breakthroughs, perhaps through combination therapies or refined targeting strategies, offer a glimmer of hope for the millions of patients worldwide suffering from this debilitating condition. GSK’s continued investment in camlipixant for IBS demonstrates the potential of this drug class, albeit in different therapeutic arenas, and the ongoing quest for novel treatments for a range of gastrointestinal and respiratory disorders.
nnnnnnn
